1600 participants enrolled for Phase III clinical trials of Covishield
SII and ICMR are conducting Phase 2/3 clinical trial of COVISHIELD at 15 different centres, across the country
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Serum Institute of India
IAVI, Merck KGaA and Serum Institute partner to develop COVID-19 mAbs
The partnership aims to ensure access to a class of innovative therapies that have, to date, been out of reach in low- and…
Serum Institute to produce up to additional 100 mn COVID-19 vaccine doses for India and LMIC in 2021
The arrangement again provides an option to secure additional doses if the vaccines pillar of the Access to COVID-19 Tools…
Serum Institute starts manufacturing Codagenix’s COVID-19 vaccine candidate
CDX-005, an intranasal, live-attenuated vaccine candidate, has completed preclinical animal studies, and Codagenix expects to…
Serum Institute receives DCGI approval to resume trials of Oxford COVID-19 vaccine
The DCGI has, however, put certain conditions like taking extra care during screening, providing additional information in…
Why COVID-19 presents a golden opportunity to Indian pharma firms
Juilee Dandekar, Sector Expert - Healthcare, Business Research & Advisory, Aranca informs that with India Pharma Inc's…
Novavax expands deal with Serum Institute, aims for two billion COVID-19 vaccine doses
Serum Institute will also manufacture the antigen component of the vaccine, dubbed NVX‑CoV2373
Patient activist groups express relief over pause of Covishield trials in India
They call for more timely responses and accountability on part of both regulators and companies to ensure patient safety
SII pauses trials of COVID-19 vaccine candidate Covishield in India
The company took this step after the DCGI issued a show cause notice to the company for not informing it about AstraZeneca…
DCGI issues notice to Serum Institute over AstraZeneca-Oxford COVID-19 vaccine trial suspension
If DCGI has any safety concerns, we will follow their instructions and abide by the standard protocol, said SII in response to…